IS THERE A PLACE FOR IMMUNOTHERAPY WITH INTERLEUKIN-2 TO PREVENT RELAPSE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR ACUTE-LEUKEMIA

被引：13

作者：

KLINGEMANN, HG

PHILLIPS, GL

机构：

[1] The Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver Hospital and Health Sciences Center, BC Cancer Agency, Terry Fox Laboratory and the Department of Medicine, University of British Columbia, Vancouver

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 16卷 / 5-6期

关键词：

INTERLEUKIN-2; ACUTE LEUKEMIA; BONE MARROW TRANSPLANTATION;

D O I：

10.3109/10428199509054425

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Chemotherapy-resistant cells cause disease recurrence in a significant proportion of patients with acute leukemia treated with autologous stem cell transplantation due to the lack of immune-mediated effects which contribute significantly to the prevention of post-treatment disease recurrence. This conclusion is based on the observation that relapse after high dose chemotherapy supported by a stem cell transplant from a twin donor is 3-4 times higher than after transplant from an allogeneic donor. This anti-leukemic mechanism of transplanted donor cells has been termed graft-versus-leukemia (GVL) effect, and efforts are being directed toward utilizing such an immune-mechanism after autologous transplantation. Since interleukin-2 (IL-2) can induce remissions in selected patients with advanced leukemia, it has become a candidate cytokine to be used in attempts to introduce GVL after autologous stem cell transplantation. Here we review the available clinical data with IL-2 and critically evaluate whether IL-2 has a place as adjunct treatment to prevent relapse after autologous transplantation for acute leukemia.

引用

页码：397 / 405

页数：9

共 88 条

[1]

Gale R.P., Champlin R.E., How does bone marrow transplantation cure leukaemia?, Lancet, 2, pp. 28-30, (1984)

[2]

Fefer A., Sullivan K.M., Weiden P., Graft-versus-leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation, Prog. Clin. Biol. Res., 244, pp. 401-408, (1987)

[3]

Phillips G.L., Reece D.E., Shepherd J.D., Barnett M.J., Brown R.A., Frei-Lahr D.A., Klingemann H.-G., Boswell B.J., Spinelli J.J., Herzig R.H., Herzig G.P., High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults, Blood, 11, pp. 1429-1435, (1991)

[4]

Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., Storb R., Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts, N. Engl. J. Med., 300, pp. 1068-1073, (1979)

[5]

Sullivan K.M., Weiden P.L., Storb R., Witherspoon R.P., Fefer A., Fisher L., Buckner C.D., Anasetti C., Appelbaum F.R., Badger C., Beatty P., Bensinger W., Berenson R., Bigelow C., Cheever M.A., Clift R., Deeg H.J., Doney K., Greenberg P., Hansen J.A., Hill R., Loughran T., Martin P., Neiman P., Petersen F.B., Sanders J., Singer J., Stewart P., Thomas E.D., Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical sibli

[6]

Verdonck L.F., ban Heugten H.G., Giltay J., Franks C.R., Amplification of the graft-versus-leukemia effect in man by interleukin-2, Transplantation, 51, pp. 1120-1123, (1991)

[7]

Klingemann H.-G., Phillips G.L., Immunotherapy after bone marrow transplantation, Bone Marrow Transplant., 8, pp. 73-81, (1991)

[8]

Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.-J., Rimm A.A., Ringden O., Rozman C., Speck B., Truitt R.L., Zwaan F.E., Bortin M.M., Graft-versus-leukemia reactions after bone marrow transplantation, Blood, 75, pp. 555-562, (1990)

[9]

Champlin R., Gale R.P., Acute lymphoblastic leukemia: Recent advances in biology and therapy, Blood, 73, pp. 2051-2066, (1989)

[10]

Kersey J.H., Weisdorf D., Nesbit M.E., LeBien T.W., Woods W.G., McGlave P.B., Kim T., Vallera D.A., Goldman A.I., Bostrom B., Hurd D., Ramsay N.K.C., Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia, N. Engl. J. Med., 317, pp. 461-467, (1987)

← 1 2 3 4 5 6 7 8 9 →